28 sept. 2017 - FDA sent letters to IR opioid analgesic manufacturers informing them that their products that are intended to be used in the outpatient setting will be subject to the same REMS requirements as the ER/LA opioid analgesics.
Ajouté au bande de temps:
Date:
28 sept. 2017
Maintenaint
~ Il y a 8 ans